Column Group LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Column Group LLC reported 5 stock positions worth $55.7 million. Its top holding was Oric Pharmaceuticals (ORIC) at 51.3% of the portfolio, followed by Tenaya Therapeutics (TNYA, 24.1%) and Surrozen (SRZN, 20.9%). Compared with Q3 2024, it sold out of 1 and reduced 1. The biggest sale was Rapt Therapeutics (shares −50%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001833486
- Portfolio Value
- $55.7M (Q4 2024)
- SEC Filing
- 0000950123-25-002782 ↗ filed Feb 14, 2025
Holdings Value
Holdings 5 stocks · $55.7M
| ORIC Oric Pharmaceuticals Inc. | 51.26% | 3,540,777 | $28.6M | No change |
| TNYA Tenaya Therapeutics Inc. | 24.12% | 9,400,290 | $13.4M | No change |
| SRZN Surrozen Inc. | 20.85% | 810,088 | $11.6M | No change |
| RAPT THERAPEUTICS INC | 3.77% | 1,328,613 | $2.1M | Reduce -50.4% |
| RVMD Revolution Medicines Inc. | 0.00% | 46 | $2K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| RAPT THERAPEUTICS INC | Reduce -50.4% | 3.77% | −3.98 |
| SGMT Sagimet Biosciences Inc. Class A | Sold out | 0.00% | −0.07 |
Portfolio Buys Q3 2024 → Q4 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $88.1M | SRZN, ORIC, RVMD |
| Q1 2026 | 3 | $100.7M | SRZN, ORIC, RVMD |
| Q4 2025 | 5 | $82.8M | SRZN, ORIC, TNYA, RAPT THERAPEUTICS INC, RVMD |
| Q3 2025 | 5 | $81.0M | ORIC, SRZN, TNYA, RAPT THERAPEUTICS INC, RVMD |
| Q2 2025 | 5 | $65.7M | ORIC, SRZN, RAPT THERAPEUTICS INC, TNYA, RVMD |
| Q1 2025 | 5 | $44.2M | ORIC, SRZN, TNYA, RAPT THERAPEUTICS INC, RVMD |
| Q4 2024 | 5 | $55.7M | ORIC, TNYA, SRZN, RAPT THERAPEUTICS INC, RVMD |
| Q3 2024 | 6 | $69.6M | ORIC, TNYA, SRZN, RAPT THERAPEUTICS INC, SGMT |
| Q2 2024 | 6 | $71.3M | TNYA, ORIC, SRZN, RAPT THERAPEUTICS INC, SGMT |
| Q1 2024 | 7 | $160.5M | TNYA, ORIC, NGM, RAPT THERAPEUTICS INC, SRZN |